Third Party Funding
Budget year/Third-party funds/Funding Organisation and name of the project
2024-2027: 445,035.00 €, DFG/ Gpcpd1
2024-2027: 679,138.69 €, BMBF/ LiSyM-Krebs Phase II
2024-2027: 402,844.00 €, DFG/ CholNeph
2024-2029: 358,145.00 €, Deutsche Krebshilfe/ TACTIC
2023-2026: 379,573.00 €, DFG/ Ductmo
2023-2026: 983,250.00 €, DFG/ SKLM
2023-2026: 377,000.00 €, DFG/ APAP-Hepatotoxizität
2021-2028: 251,000.00 €, EU/ PARC
2021-2024: 276,626.00 €, DFG/ LPA bei Eierstockkrebs
2021-2024: 1,056,955.00 €, BMBF/ LiSyM-Krebs
2021-2024: 477,300.00 € DFG/ NAFLD-NASH-HCC
2021-2023: 256,385.36 €, BMBF/ SteatoTox-2
2021: 18,000.00 €, BfR
2020-2024: 154,000.00 €, BMBF/ InnoSysTox-Moving
2020-2023: 230,000.00 €, Deutsche Krebshilfe/ HER2+
2020-2022: 859,650.00 €, DFG/ SKLM
2018-2021: 350,910.00 €, BMBF/ SteatoTox
2018-2020: 76,750.00 €, DFG/ NK-DILI-ILC2
2018-2019: 3,000.00 €, IPB Halle/ Bioactive Compounds
2018-2019: 771,150.00 €, DFG/ SKLM
2017-2022: 1,182,296.00 €, Land NRW/ Drug Discovery Hub
2017-2021: 186,702.00 $, Thomas Jefferson University/ Multiscale Modeling
2017-2020: 263,702.00 €, DFG/ IL-15
2017-2022: 350,250.00 €, EU/ IMI Trans QST
2017-2020: 281,118.90 €, DLR/ StemCellNet
2017-2020: 246,765.00 €, BMBF/ SysDT Transfer
2017-2020: 345,602.00 €, BMBF/ LivSys Transfer
2017-2018: 14,824.00 €, DAAD/ Norwegen
2016-2021: 2,802,501.00 €, BMBF/ LiSym (Pillar II/III)
2016-2021: 2,212,235.00 €, BMBF/ LiSym (Vartak)
2016-2021: 1,276,732.00 €, BMBF/ LiSym (Ghallab)
2016-2021: 930,375.00 €, EU/ EUToxRisk21
2016-2019: 250,800.00 €, BMBF/ DILI
2016-2019: 134,710.00 €, BMBF/ InnoSysTox
2016-2019: 225,300.00 €, DFG/ WISP1-II
2016-2019: 324,400.00 €, DFG/ EDI3
2016-2019: 168,493.80 €, Fachagentur Nachwachsende Rohstoffe e.V. (FNR)/ GesundHolz
2016-2018: 400,000.00 €, DGUV/ IRRE IV
2016: 1,485.00 €, Universität Wageningen/ Occupational Toxicology 2016
2014-2017: 10,000.00 €, ANKÜR/ Boren II
2014-2017: 493,770.00 €, BMBF/ Verbundprojekt Lebersimulator
2014-2017: 366,329.00 €, BMBF/ LCI-MEA (Life Cell Imaging –Micro Electrode Array)
2014-2015: 134,209.00 €, BMBF/ Verbundprojekt SysDT
2014: 3,320.00 €, Universität Wageningen/ Occupational Toxicology 2014
2013-2017: 90,000.00 €, INRIA/ iFlow
2013-2015: 284,325.00 €, BMBF/ Verbundprojekt LivSys
2013-2014: 10,000.00 €, Gedek-Stiftung/ Citrinin
2012-2017: 452,952.00 €, BMBF/ DEEP
2012-2015: 275,750.00 €, EU/ Body-on-Chip
2012-2015: 1,725.00 €, DAAD/ South Asia Program,study and research subsidy
2012-2015: 45,000.00 €, DAAD /South Asia Program
2012-2013: 9,000.00 €, Eurotox
2012: 5,000.00 €, Universität Wageningen/ Occupational Toxicology 2012
2011-2016: 19,590.00 €, Lead Discovery Center /LDC
2011-2016: 881,904.60 €, DGUV/ IRRE 2
2011-2015: 618,317.00 €, EU/ DETECTIVE
2011-2015: 561,048.00 €, EU/ NOTOX
2011-2014: 395,499.00 €, BMBF/ Network Formation Assay
2011-2012: 8,300.00 €, DFG/ Internationale Kooperation Türkei
2011-2012: 10,000.00 €, Gedek-Stiftung
2010-2015: 1,745,645.00 €, BMBF/ Virtual Liver
2010-2012: 128,400.00 €, DFG/ WISP1
2009-2012: 241,848.00 €, BMBF/ Liver fibrosis
2009-2012: 370,863.00 €, EU/Land NRW/ Mykotoxine II
2009-2011: 600,000.00 €, BMBF/ Micro Fluidic
2009-2011: 500,000.00 €, BMBF/ LiverStemCell
2009-2011: 42,000.00 €, DAAD/ CONICYT (Chile Programm) Doktorandenstipendium € 14,000/Jahr
2009-2011: 33,585.00 €, DFG/ Kooperation Chile
2008-2023: 490,154.00 €, Springer-Verlag/ Archives of Toxicology
2008-2013: 790,234.00 €, EU/ Aufstockung ESNATS
2008-2013: 977,000.00 €, EU/ ESNATS
2008-2012: 406,400.00 €, BMBF/ Oncoprofile
2008-2012: 1,825.00 €, Ruhr-Universität Bochum/ Cytochrome
2008-2012: 8,000.00 €, BMBF/ “Sugar grant“ Regneration/HepatoSys
2008-2011: 854,850.00 €, EU/ CancerSys
2007-2023: 227,420.00 €, Springer-Verlag/ Toxikologische Forschung
2007-2011: 67,000.00 €, CEFIC, FKE/ Phytoöstrogene
2007-2011: 635,150.00 €, DGUV/ IRRE 1
2007-2011: 621,108.00 €, BMBF/ ToxGenom
2006-2013: 96,390.00 €, Heinrich-Heine-Univ. Düsseldorf/ DFG-Graduiertenkolleg 1427 (Degen)
2006-2013: 99,506.00 €, Heinrich-Heine-Univ. Düsseldorf/ DFG- Graduiertenkolleg 1427 (Roos)